title: [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
abstract: OBJECTIVE
  To evaluate, in breast cancer patients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete pathological response (pCR).
  
  
  METHODS
  Forty-seven women with non-metastatic, non-inflammatory, large or locally advanced breast cancer were included. Tumour uptake of FDG was evaluated before and after the first course of neoadjuvant chemotherapy. Four indices were used: maximal and average SUV without or with correction by body surface area and glycaemia (SUV(max), SUV(avg), SUV(max-BSA-G) and SUV(avg-BSA-G), respectively). The predictive value of reduction in FDG uptake with respect to pCR was studied by logistic regression analysis. Relationships between baseline [(18)F]FDG uptake and prognostic parameters were assessed.
  
  
  RESULTS
  The relative decrease in FDG uptake (DeltaSUV) after the first course of neoadjuvant chemotherapy was significantly greater in the pCR group than in the non-pCR group (p < 0.000066). The four FDG uptake indices were all strongly correlated with each other. A decrease in SUV(max-BSA-G) of 85.4% +/- 21.9% was found in pCR patients, versus 22.6% +/- 36.6% in non-pCR patients. DeltaSUV(max-BSA-G) <-60% predicted the pCR with an accuracy of 87% and DeltaSUVs were found to be only factors predictive of the pCR at multivariate analysis. An elevated baseline SUV was associated with high mitotic activity (p < 0.0016), tumour grading (p < 0.004), high nuclear pleomorphism score (p < 0.03) and negative hormonal receptor status (p < 0.005).
  
  
  CONCLUSIONS
  In breast cancer patients, after only one course of neoadjuvant chemotherapy the reduction in FDG uptake is an early and powerful predictor of pCR.
authors.affiliation: Department of Nuclear Medicine, Centre Georges Francois Leclerc, Dijon, France. ariedinger@dijon.fnclcc.fr
authors.forename: Alina
authors.initials: A
authors.lastname: Berriolo-Riedinger
authors.forename: Claude
authors.initials: C
authors.lastname: Touzery
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Riedinger
authors.forename: Michel
authors.initials: M
authors.lastname: Toubeau
authors.forename: Bruno
authors.initials: B
authors.lastname: Coudert
authors.forename: Laurent
authors.initials: L
authors.lastname: Arnould
authors.forename: Christophe
authors.initials: C
authors.lastname: Boichot
authors.forename: Alexandre
authors.initials: A
authors.lastname: Cochet
authors.forename: Pierre
authors.initials: P
authors.lastname: Fumoleau
authors.forename: François
authors.initials: F
authors.lastname: Brunotte
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18